Solid Biosciences (SLDB) Stock Forecast & Price Target

Solid Biosciences is viewed favorably because SGT-003 appears differentiated in DMD through muscle-targeting capsid engineering, preserved nNOS signaling, and a cleaner steroid-only safety profile, with no drug-induced liver injury reported across 53 dosed patients and only two treatment-related SAEs that resolved. The company also has meaningful regulatory optionality, as the FDA has already acknowledged high unmet need and a novel construct, while the late-4Q26 meeting comes alongside a randomized confirmatory trial already underway, reducing development risk. Beyond DMD, the pipeline adds upside with SGT-212 in Friedreich’s ataxia showing strong preclinical survival and cardiac signals, and the stock’s ~$700m EV and ~$393m net cash leave room for upside if the biomarker package translates into function.

Solid Biosciences is challenged by a highly uncertain pipeline, because its lead programs still face unproven registrational paths, high regulatory bars, and the risk that safety signals or insufficient efficacy could derail approval across DMD, FA, and CPVT. The company’s financial position is also fragile, with about $236 million in cash, cash equivalents, investments, and available-for-sale securities as of September 30, 2025, leaving it likely dependent on future partnerships or financings to fund development and eventual commercialization. Competitive pressure from multiple programs in DMD and FA, combined with the possibility of long-term pricing pressure and commercial execution risk, could sharply limit value even if one or more assets reach the market.